Evidence map›Paper›PMID 34996976›Full record

ArticleScientific reports2022

SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity.

Mariusz Berdyński, Przemysław Miszta, Krzysztof Safranow, Peter M Andersen, Mitsuya Morita, Sławomir Filipek, Cezary Żekanowski, Magdalena Kuźma-Kozakiewicz

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 3 pooled it
19.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 3 syntheses or guidelines pooled it, 165 citations in OpenAlex.

  1. Pooled it
  2. Safety and efficacy of arimoclomol in amyotrophic lateral sclerosis: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Cerebellar ataxia-onset ALS withFrontiers in neurology · 2026
    Article

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Mariusz Berdyński *Laboratory of Neurogenetics, Department of Neurodegenerative Disorders, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland. m.berdynski@imdik.pan.pl.
Przemysław Miszta *Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Warsaw, Poland.
Krzysztof Safranow *Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 72 Powstańców Wlkp. Str., 70-111, Szczecin, Poland.
Peter M AndersenDepartment of Clinical Sciences, Neurosciences, Umeå University, Umeå, Sweden.
Mitsuya MoritaDivision of Neurology, Department of Internal Medicine, Jichi Medical University, Shimotsuke, Japan.
Sławomir FilipekFaculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Warsaw, Poland.
Cezary ŻekanowskiLaboratory of Neurogenetics, Department of Neurodegenerative Disorders, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.
Magdalena Kuźma-KozakiewiczDepartment of Neurology, Medical University of Warsaw, Warsaw, Poland. mkuzma@wum.edu.pl.
Polish Academy of Sciences · PLUniversity of Warsaw · PLJichi Medical University · JPMedical University of Warsaw · PLPomeranian Medical University · PLUmeå University · SE

Funding

EU Joint Programme - Neurodegenerative Disease Research SOPHIA (5/SOPHIA/JPND/2012)Narodowym Centrum Nauki SONATA9 [UMO-2015/17/D/NZ2/03712]
6 · The paper itself

Abstract

Mutations in superoxide dismutase 1 gene (SOD1) are linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder predominantly affecting upper and lower motor neurons. The clinical phenotype of ALS shows inter- and intrafamilial heterogeneity. The aim of the study was to analyze the relations between individual SOD1 mutations and the clinical presentation using in silico methods to assess the SOD1 mutations severity. We identified SOD1 causative variants in a group of 915 prospectively tested consecutive Polish ALS patients from a neuromuscular clinical center, performed molecular modeling of mutated SOD1 proteins and in silico analysis of mutation impact on clinical phenotype and survival analysis of associations between mutations and hazard of clinical end-points. Fifteen SOD1 mutations were identified in 21.1% familial and 2.3% sporadic ALS cases. Their effects on SOD1 protein structure and functioning inferred from molecular modeling and in silico analyses correlate well with the clinical data. Molecular modeling results support the hypothesis that folding intermediates rather than mature SOD1 protein give rise to the source of cytotoxic conformations in ALS. Significant associations between type of mutation and clinical end-points were found.

Indexed as

MutationAdultAgedAmyotrophic Lateral SclerosisFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHumansMaleMiddle AgedModels, MolecularMutation RatePatient AcuityPhenotypePolandPrognosisSOD1 protein, humanSuperoxide Dismutase-1

Identifiers

PMID34996976
PMCPMC8742055
OpenAlexW4206363717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.